141 related articles for article (PubMed ID: 31529281)
1. Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy.
Tiribelli M; Abruzzese E; Capodanno I; Sorà F; Trabacchi E; Iurlo A; Luciano L; Binotto G; Bonifacio M; Annunziata M; Crugnola M; Fanin R
Ann Hematol; 2019 Nov; 98(11):2609-2611. PubMed ID: 31529281
[No Abstract] [Full Text] [Related]
2. Bosutinib - related pleural effusion in patients with chronic myeloid leukemia.
Yüzbaşıoğlu MB; Eşkazan AE
Expert Opin Drug Saf; 2021 Apr; 20(4):379-381. PubMed ID: 33339467
[No Abstract] [Full Text] [Related]
3. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
García-Gutiérrez V; Milojkovic D; Hernandez-Boluda JC; Claudiani S; Martin Mateos ML; Casado-Montero LF; González G; Jimenez-Velasco A; Boque C; Martinez-Trillos A; Vázquez IM; Payer ÁR; Senín A; Amustio Díez E; García AB; Carrascosa GB; Ortí G; Ruiz BC; Fernández MÁ; Del Carmen García Garay M; Giraldo P; Guinea JM; De Las Heras Rodríguez N; Hernán N; Pérez AI; Piris-Villaespesa M; Lorenzo JLL; Martí-Tutusaus JMM; Vallansot RO; Ortega Rivas F; Puerta JM; Ramirez MJ; Romero E; Romo A; Rosell A; Saavedra SS; Sebrango A; Tallon J; Valencia S; Portero A; Steegmann JL;
Ann Hematol; 2019 Feb; 98(2):321-330. PubMed ID: 30446802
[TBL] [Abstract][Full Text] [Related]
4. Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice.
Caocci G; Mulas O; Abruzzese E; Iurlo A; Annunziata M; Orlandi EM; Galimberti S; Binotto G; Sgherza N; Luciano L; Martino B; Russo Rossi A; Bonifacio M; Fozza C; Trawinska MM; Cattaneo D; Elena C; Baratè C; De Gregorio F; Molica M; La Nasa G; Foà R; Breccia M
Ann Hematol; 2019 Aug; 98(8):1885-1890. PubMed ID: 31044260
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia.
Fujiwara SI; Shirato Y; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Minakata D; Nakano H; Morita K; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Int J Hematol; 2018 Jun; 107(6):712-715. PubMed ID: 29185155
[TBL] [Abstract][Full Text] [Related]
6. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
Jain AG; Gesiotto Q; Ball S; Nodzon L; Rodriguez A; Chan O; Padron E; Kuykendall A; Komrokji R; Sallman DA; Lancet JE; Pinilla-Ibarz J; Sweet K
Ann Hematol; 2024 Jun; 103(6):1941-1945. PubMed ID: 38634915
[TBL] [Abstract][Full Text] [Related]
7. Long-term cardiac, vascular, hypertension, and effusion safety of bosutinib in patients with Philadelphia chromosome-positive leukemia resistant or intolerant to prior therapy.
Cortes JE; Kantarjian HM; Mauro MJ; An F; Nick S; Leip E; Gambacorti-Passerini C; Brümmendorf TH
Eur J Haematol; 2021 Jun; 106(6):808-820. PubMed ID: 33638218
[TBL] [Abstract][Full Text] [Related]
8. The safety of Bosutinib for the treatment of chronic myeloid leukemia.
Kong JH; Khoury HJ; Kim AS; Hill BG; Kota V
Expert Opin Drug Saf; 2017 Oct; 16(10):1203-1209. PubMed ID: 28774214
[TBL] [Abstract][Full Text] [Related]
9. The European medicines agency review of bosutinib for the treatment of adult patients with chronic myelogenous leukemia: summary of the scientific assessment of the committee for medicinal products for human use.
Hanaizi Z; Unkrig C; Enzmann H; Camarero J; Sancho-Lopez A; Salmonson T; Gisselbrecht C; Laane E; Pignatti F
Oncologist; 2014 Apr; 19(4):421-5. PubMed ID: 24668331
[TBL] [Abstract][Full Text] [Related]
10. Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors.
Caocci G; Mulas O; Annunziata M; Luciano L; Abruzzese E; Bonifacio M; Orlandi EM; Albano F; Galimberti S; Iurlo A; Pregno P; Sgherza N; Martino B; Binotto G; Castagnetti F; Gozzini A; Bocchia M; Fozza C; Stagno F; Simula MP; De Gregorio F; Trawinska MM; Scaffidi L; Elena C; Attolico I; Baratè C; Cattaneo D; Pirillo F; Gugliotta G; Sicuranza A; Molica M; La Nasa G; Foà R; Breccia M
Int J Cardiol; 2020 Feb; 301():163-166. PubMed ID: 31711851
[TBL] [Abstract][Full Text] [Related]
11. Deterioration of pulmonary hypertension and pleural effusion with bosutinib following dasatinib lung toxicity.
Riou M; Seferian A; Savale L; Chaumais MC; Guignabert C; Canuet M; Magro P; Rea D; Sitbon O; Jaïs X; Humbert M; Montani D
Eur Respir J; 2016 Nov; 48(5):1517-1519. PubMed ID: 27799395
[No Abstract] [Full Text] [Related]
12. Efficacy and safety following bosutinib dose reduction in patients with Philadelphia chromosome‒positive leukemias.
Kota V; Brümmendorf TH; Gambacorti-Passerini C; Lipton JH; Kim DW; An F; Leip E; Crescenzo RJ; Ferdinand R; Cortes JE
Leuk Res; 2021 Dec; 111():106690. PubMed ID: 34673442
[TBL] [Abstract][Full Text] [Related]
13. TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
Claudiani S; Apperley JF; Szydlo R; Khan A; Nesr G; Hayden C; J Innes A; Dominy K; Foskett P; Foroni L; Khorashad J; Milojkovic D
Br J Haematol; 2021 Apr; 193(2):346-355. PubMed ID: 33368155
[TBL] [Abstract][Full Text] [Related]
14. Long-term treatment with bosutinib in a phase 1/2 study in Japanese chronic myeloid leukemia patients resistant/intolerant to prior tyrosine kinase inhibitor treatment.
Takahashi N; Nakaseko C; Kobayashi Y; Miyamura K; Ono C; Koide Y; Fujii Y; Ohnishi K
Int J Hematol; 2017 Sep; 106(3):398-410. PubMed ID: 28409328
[TBL] [Abstract][Full Text] [Related]
15. Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemia.
Keller-V Amsberg G; Brümmendorf TH
Expert Rev Anticancer Ther; 2012 Sep; 12(9):1121-7. PubMed ID: 23098112
[TBL] [Abstract][Full Text] [Related]
16. Development of Philadelphia chromosome-negative acute myeloid leukemia with IDH2 and NPM1 mutations in a patient with chronic myeloid leukemia who showed a major molecular response to tyrosine kinase inhibitor therapy.
Nakamura F; Arai H; Nannya Y; Ichikawa M; Furuichi S; Nagasawa F; Takahashi W; Handa T; Nakamura Y; Tanaka H; Nakamura Y; Sasaki K; Miyano S; Ogawa S; Mitani K
Int J Hematol; 2021 Jun; 113(6):936-940. PubMed ID: 33400143
[TBL] [Abstract][Full Text] [Related]
17. Effects of SLC22A2 808G>T polymorphism and bosutinib concentrations on serum creatinine in patients with chronic myeloid leukemia receiving bosutinib therapy.
Abumiya M; Takahashi N; Takahashi S; Yoshioka T; Kameoka Y; Miura M
Sci Rep; 2021 Mar; 11(1):6362. PubMed ID: 33737618
[TBL] [Abstract][Full Text] [Related]
18. [New treatment option for patient with CML-bosutinib].
Takahashi N
Gan To Kagaku Ryoho; 2015 May; 42(5):563-7. PubMed ID: 26054091
[No Abstract] [Full Text] [Related]
19. Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Kojima M; Nakamura N; Amaki J; Numata H; Miyaoka M; Motoori T; Matsumoto K; Ando K
J Clin Exp Hematop; 2017; 57(2):69-73. PubMed ID: 29021516
[TBL] [Abstract][Full Text] [Related]
20. Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine-kinase inhibitors.
Latagliata R; Attolico I; Trawinska MM; Capodanno I; Annunziata M; Elena C; Luciano L; Crugnola M; Bergamaschi M; Bonifacio M; Baratè C; Mauro E; Binotto G; Sgherza N; Aguzzi C; Monteleone B; Sorà F; Caocci G; Luzi D; Mariggiò E; Scaffidi L; Cattaneo D; Gozzini A; Di Veroli A; Abruzzese E; Galimberti S; Iurlo A; Specchia G; Breccia M
Hematol Oncol; 2021 Aug; 39(3):401-408. PubMed ID: 33617659
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
